Your session is about to expire
← Back to Search
Durvalumab + Chemotherapy for Lung Cancer (AEGEAN Trial)
AEGEAN Trial Summary
This trial is testing a new cancer treatment combining a drug called durvalumab with chemotherapy. The study will compare how well the new treatment works compared to chemotherapy alone.
AEGEAN Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAEGEAN Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 80 Patients • NCT03015129AEGEAN Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am fully active or restricted in physically strenuous activity but can do light work.I do not have active infections like TB, hepatitis B or C, or HIV.I have at least one cancer spot that can be measured and hasn't been treated with radiation.I have not had treatments like immunotherapy for my condition.I have a new, untreated lung cancer that can be surgically removed.I have provided a biopsy sample for EGFR and ALK testing.My cancer has a confirmed EGFR mutation or ALK translocation.I have cancer that has spread to my brain or spinal cord.I have had another type of cancer before.My organs and bone marrow are working well.My upcoming surgery is a lobectomy, sleeve resection, or bilobectomy.Making sure the patient's tumor has a certain PD-L1 status.I am scheduled for radiotherapy before surgery as part of my treatment.My lung cancer is at an advanced stage (IIIB N3, IIIC, IVA, or IVB).I have received an organ transplant from another person.My lung cancer cannot be removed with surgery.I have more than one type of lung cancer.My upcoming surgery involves removing part or all of a lung.I am 18 years old or older.I have or had an autoimmune or inflammatory disorder.You have a history of ongoing problems with your immune system.
- Group 1: Arm 2: Placebo with platinum-based chemotherapy
- Group 2: Arm 1: Durvalumab with platinum-based chemotherapy
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this study limited to senior citizens, or will other age groups be considered?
"The aim of this study is to enroll patients who are between the ages of 18 and 120."
How can I sign up to participate in this research project?
"Eligible patients for this study must have non-small cell lung carcinoma (nsclc), be between 18 and 120 years old, and there are looking to enroll 816 total patients."
Are there any slots left for participants in this experiment?
"The clinical trial in question is not, at present, actively recruiting patients. According to the information available on clinicaltrials.gov, the study was first posted on December 6th 2018 and last updated on August 16th 2022. There are, however, 4111 other studies that are presently looking for candidates."
Are there any severe side effects associated with Durvalumab?
"There is both pre-existing data and clinical evidence supporting the safety of Durvalumab, thus it received a score of 3."
What is the primary illness that Durvalumab has been known to target?
"Durvalumab has multiple approved indications, including the treatment of metastatic ureter urothelial carcinoma, lymphoma, and locally advanced non-small cell lung cancer."
How many people are going to be participating in this clinical trial?
"This study is no longer taking in new participants. It was first posted on December 6th, 2018 and most recently updated on August 16th, 2022. For those still interested in participating in non-small cell lung carcinoma (nsclc) research, there are presently 2095 trials actively admitting patients. Additionally, 2016 studies for Durvalumab are also seeking participants."
Share this study with friends
Copy Link
Messenger